What is Viome?
Viome operates at the forefront of the health-tech sector, specializing in at-home microbiome analysis that informs personalized nutrition and supplement regimens. By utilizing advanced artificial intelligence and proprietary RNA sequencing, the company provides users with deep insights into their gut, oral, and systemic health. This data-centric approach allows Viome to move beyond generic wellness advice, offering tailored dietary solutions that address the root causes of chronic health conditions. The company serves a diverse demographic, ranging from health-conscious individuals and athletes to professional health coaches, positioning itself as a critical player in the burgeoning longevity and preventative medicine market.
How much funding has Viome raised?
Viome has raised a total of $163M across 5 funding rounds:
Series A
$15M
Series B
$5.5M
Debt
$2M
Other Financing Round
$54M
Series C
$86.5M
Series A (2017): $15M with participation from BOLD CAPITAL PARTNERS and Khosla Ventures
Series B (2018): $5.5M led by Physician Partners and Khosla Ventures
Debt (2020): $2M supported by PPP
Other Financing Round (2021): $54M featuring Physician Partners, Khosla Ventures, Glico, WestRiver Group, and BOLD Capital Group
Series C (2023): $86.5M backed by WRG Ventures, BOLD Capital Group, and Khosla Ventures
Key Investors in Viome
Khosla Ventures
A prominent venture capital firm founded by Vinod Khosla, specializing in breakthrough technologies across sectors including health, AI, and enterprise software.
BOLD Capital Group
A private investment and advisory firm focused on early-stage technology platforms, providing strategic support to companies in healthcare, blockchain, and cybersecurity.
WestRiver Group
A thematically-driven investment platform that directs capital toward purpose-driven enterprises within the global innovation economy to enhance societal well-being.
What's next for Viome?
With the recent influx of $86.5M, Viome is well-positioned to scale its operational infrastructure and expand its research and development capabilities. The company is expected to leverage this capital to enhance its AI-driven diagnostic platform, potentially broadening its test offerings to include more comprehensive health intelligence metrics. As the market for personalized health continues to mature, Viome's strategic focus will likely shift toward deeper clinical integration and the expansion of its digital health ecosystem. By maintaining its commitment to data-driven longevity, the company aims to solidify its leadership in the preventative healthcare space, providing a scalable model for personalized wellness that addresses the complexities of the human microbiome.
See full Viome company page
